Evidence map›Paper›PMID 38715337›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2025

The Lifetime Health and Economic Burden of Smokeless Tobacco use in Bangladesh, India, and Pakistan: Results From ASTRAMOD.

Kathryn Coyle, Prashant Kumar Singh, Ravi Kaushik, Rumana Huque, Zohaib Khan, Ravi Mehrotra, Kamran Siddiqi, Subhash Pokhrel

Abstract read
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kathryn CoyleHealth Economics Research Group (HERG), Department of Health Sciences, Brunel University London, Uxbridge, UK.
Prashant Kumar SinghDivision of Preventive Oncology and Population Health, ICMR-National Institute of Cancer Prevention and Research, Noida, India.ORCID 0000-0003-1742-5534
Ravi KaushikDepartment of Physiology, Maulana Azad Medical College, New Delhi, India.
Rumana HuqueARK Foundation, Dhaka, Bangladesh.ORCID 0000-0002-7616-9596
Zohaib KhanOffice of Research, Innovation, and Commercialization, Khyber Medical University, Peshawar, Pakistan.ORCID 0000-0002-1885-8254
Ravi MehrotraCentre for Health Innovation and Policy (CHIP) Foundation, Noida, India.ORCID 0000-0001-9453-1408
Kamran SiddiqiDepartment of Health Sciences and Hull York Medical School, University of York, York, UK.ORCID 0000-0003-1529-7778
Subhash PokhrelHealth Economics Research Group (HERG), Department of Health Sciences, Brunel University London, Uxbridge, UK.ORCID 0000-0002-1009-8553

Funding

UK government
6 · The paper itself

Abstract

introductionUnder the current policy landscapes, the lifetime health and economic burden of smokeless tobacco (ST) products, consumed by over 297 million ST users in South Asia, is unknown. The aim of this study was to estimate the lifetime health effects and costs attributable to current and future ST use in Bangladesh, India, and Pakistan where the majority of ST users live. AIMS AND

methodsWe developed a Markov-based state-transition model (ASTRAMOD) to predict the lifetime costs of treatment of four diseases (oral, pharyngeal, esophageal cancers, and stroke) and disability-adjusted life years (DALYs), attributable to the current and future use of ST under existing ST policy scenario. Country-specific Global Adult Tobacco Surveys, life tables, and meta-analyses of South Asian and South East Asian studies were used to populate the model. A probabilistic sensitivity analysis evaluated the uncertainty in model predictions.

resultsIf there were no change in the current ST policies, the lifetime ST-attributable treatment costs would be over US$19 billion in India, over US$1.5 billion in Bangladesh, and over US$3 billion in Pakistan. For all countries, the attributable costs are higher for younger cohorts with costs declining with increasing age for those over 50. The model predicted that a typical 15-year-old male adoloscent would gain 0.07-0.18 life years, avert 0.07-0.19 DALYs, and generate a cost-savings of US$7-21 on healthcare spending if ST policies were changed to eliminate ST use.

conclusionsPolicy interventions aimed at decreasing the uptake of ST and increasing quitting success have the potential to substantially decrease the economic and health burden of ST. IMPLICATIONS: This study provides the most comprehensive estimates of the lifetime health and economic burden of ST by 5-year age and sex cohorts. This is also the first study that highlights the scale of health and economic burden of ST in Bangladesh, India, and Pakistan if there were no changes in the current ST policies. Policymakers and practitioners can use the reported data to justify their decisions to improve current ST policies and practices in their country. Researchers can use the ASTRAMOD methodology to estimate the impact of future ST policy changes.

Indexed as

Cost of IllnessTobacco, SmokelessAdolescentAdultAgedBangladeshDisability-Adjusted Life YearsFemaleHumansIndiaMaleMarkov ChainsMiddle AgedPakistanYoung Adult

Identifiers

PMID38715337
PMCPMC11931212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.